These resources can be used to find helpful information for pharmacy professionals about opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, RELISTOR, and related topics.
|
Pharmacist Testimonials See what some pharmacists have to say about their experiences with RELISTOR |
|
|
RELISTOR eDetail Participate in an interactive program about treating OIC in patients with advanced illness who are receiving palliative care and build a Virtual Sales Brochure |
|
|
Reprint Library Access journal articles |
|
Web Sites for Pharmacists Web site listings for professional guidelines and associations, journals, and government organizations |
Indication
RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR
beyond 4 months has not been studied.
Important Safety Information for RELISTOR
- RELISTOR is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction
- If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their physician
- Rare cases of gastrointestinal (GI) perforation have been reported in advanced illness patients. Use RELISTOR with caution in patients with known or suspected lesions of the GI tract
- Use of RELISTOR has not been studied in patients with peritoneal catheters
- The most common adverse reactions reported with RELISTOR compared with placebo in clinical trials were abdominal pain (28.5% vs 9.8%), flatulence (13.3% vs 5.7%), nausea (11.5% vs 4.9%), dizziness (7.3% vs 2.4%), diarrhea (5.5% vs 2.4%), and hyperhidrosis (6.7% vs 6.5%)
- Safety and efficacy of RELISTOR have not been established in pediatric patients
Please see the full Prescribing Information.